Skip to content

In 2024, we expect revenue and earnings development in our business segments as shown in the table below:

Financial targets by business segment 2024

Download(XLS, 36 KB)
Operating Companies Targets 2024 Base 20232
Fresenius Kabi    
Revenue growth (organic) Mid-single-digit percentage growth €8,009 m
EBIT margin1 Around 15% (structural margin band: 14-17%) €1,145 m
Fresenius Helios    
Revenue growth (organic) Low-to-mid-single-digit percentage growth €11,952 m
EBIT margin1 Within the structural margin band of 9-11% €1,190 m
Investment Company Fresenius Vamed
Revenue growth (organic3) Mid-single-digit percentage growth €2,201 m
EBIT margin1 1-2 percentage points below the structural margin band of 4-6% -€16 m
1 Before special items
2 Base 2023 adjusted
3 Calculated for continued business

Base for guidance 2024

Download(XLS, 36 KB)
  Achieved 2023 Portfolio
adjustment
Fresenius Helios
Discontinued
business
Fresenius Vamed2
Base
Guidance 2024
Group        
Revenue €22,299 million -€368 million -€155 million €21,776 million
EBIT1 €2,262 million -€42 million €0 million €2,220 million
Operating Companies        
Fresenius Kabi        
Revenue €8,009 million     €8,009 million
EBIT1 €1,145 million     €1,145 million
Fresenius Helios        
Revenue €12,320 million -€368 million   €11,952 million
EBIT1 €1,232 million -€42 million   €1,190 million
Investment Company        
Fresenius Vamed        
Revenue €2,356 million   -€155 million €2,201 million
EBIT1 -€16 million   €0 million -€16 million
Corporate        
Revenue -€386 million     -€386 million
EBIT1 -€99 million     -€99 million
1 Before special items
2 Existing projects in respective countries will continue for a certain time period

Social Media

Follow us on Social Media

Share Price

Data is delayed by 15 minutes.

Share Price Information

Contact

Fresenius SE & Co. KGaA
Investor Relations
+49 (0) 6172 608-2485
ir-fre@fresenius.com